Anavex Stock: The Pediatric Rett Trial Failure Is Disastrous (NASDAQ:AVXL)


Arrows are not targeted, Failure to attack the target. unsuccessful.


In my October article, I discussed the statistical basis for saying that the Anavex Life Sciences (AVXL) Alzheimer’s trial was a failure. This trial of blarcamesine, the company said, demonstrated slowing of cognitive decline in a key phase 2b/3

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *